2017 Bristol-Myers Squibb - UCLA Lectureship
Discovery of Pyridine Amide Based Inhibitors of Interleukin Receptor- Associated Kinase 4 (IRAK4) for the Treatment of LupusSpeaker: Dr. John Hynes,
Senior Principal Scientist, Immunology Discovery Chemistry, Bristol-Myers Squibb Co.
IRAK4 is a member of the IRAK family of serine-threonine kinases which signals downstream of toll-like receptors (TLRs) and IL-1 receptors. TLRs are centrally critical to innate immune system defense due to their ability to recognize molecular patterns associated with various pathogens. These receptors also detect damage-associated molecular pathogens (DAMPs) generated in the course of chronic autoimmune disease states such as lupus. The location of IRAK4 downstream of these innate immune system signaling receptors has resulted in significant interest in therapeutic targeting of IRAK4 in autoimmune diseases.
When: May 18, 2017, 1:30 pm
Where: Cram Conference Room - 3440 Molecular Sciences Bldg., UCLA
Bristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases.
Each day, our employees around the world work together for patients – it drives everything we do. We are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through our R&D organization, we have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate our work.